BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19066270)

  • 1. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
    Pottier N; Yang W; Assem M; Panetta JC; Pei D; Paugh SW; Cheng C; Den Boer ML; Relling MV; Pieters R; Evans WE; Cheok MH
    J Natl Cancer Inst; 2008 Dec; 100(24):1792-803. PubMed ID: 19066270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coffin-Siris syndrome is a SWI/SNF complex disorder.
    Tsurusaki Y; Okamoto N; Ohashi H; Mizuno S; Matsumoto N; Makita Y; Fukuda M; Isidor B; Perrier J; Aggarwal S; Dalal AB; Al-Kindy A; Liebelt J; Mowat D; Nakashima M; Saitsu H; Miyake N; Matsumoto N
    Clin Genet; 2014 Jun; 85(6):548-54. PubMed ID: 23815551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression.
    Pottier N; Cheok MH; Yang W; Assem M; Tracey L; Obenauer JC; Panetta JC; Relling MV; Evans WE
    Hum Mol Genet; 2007 Oct; 16(19):2261-71. PubMed ID: 17616514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma.
    Keenen B; Qi H; Saladi SV; Yeung M; de la Serna IL
    Oncogene; 2010 Jan; 29(1):81-92. PubMed ID: 19784067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms.
    Howitt BE; Folpe AL
    Genes Chromosomes Cancer; 2021 Mar; 60(3):190-209. PubMed ID: 33252159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis.
    Zhong R; Liu L; Tian Y; Wang Y; Tian J; Zhu BB; Chen W; Qian JM; Zou L; Xiao M; Shen N; Yang H; Lou J; Qiu Q; Ke JT; Lu XH; Wang ZL; Song W; Zhang T; Li H; Wang L; Miao XP
    Sci Rep; 2014 Feb; 4():4147. PubMed ID: 24556940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
    Hulleman E; Kazemier KM; Holleman A; VanderWeele DJ; Rudin CM; Broekhuis MJ; Evans WE; Pieters R; Den Boer ML
    Blood; 2009 Feb; 113(9):2014-21. PubMed ID: 18978206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWI/SNF complex-deficient soft tissue neoplasms: An update.
    Schaefer IM; Hornick JL
    Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.
    Bakshi R; Hassan MQ; Pratap J; Lian JB; Montecino MA; van Wijnen AJ; Stein JL; Imbalzano AN; Stein GS
    J Cell Physiol; 2010 Nov; 225(2):569-76. PubMed ID: 20506188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.
    Ondrušová L; Vachtenheim J; Réda J; Záková P; Benková K
    PLoS One; 2013; 8(1):e54110. PubMed ID: 23349796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
    Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.